QSAM Biosciences Inc. QSAM Archives - Page 2 of 2

FridayJul 22, 2022 2:13 pm

QualityStocksNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients,” a recent article reads. “CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. … CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters…

TuesdayJul 19, 2022 9:45 am

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEO Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells QSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its…

WednesdayJul 13, 2022 4:07 pm

QualityStocksNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (“CycloSam(R)”), for the treatment of cancer and related diseases. The company today announced that the United States Patent & Trademark Office has granted a key patent protecting how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs. “This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14…

ThursdayJul 07, 2022 9:45 am

QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities than prior FDA-approved drugs There is significant precedent that the radioisotope used in CycloSam, Samarium-153, is effective in treating bone cancer, as demonstrated in a published study conducted in over 500 patients using an older formulation of the drug There is also significant preliminary safety…

Site Search

Company Search

Tag: QSAM Biosciences Inc. QSAM

QualityStocksNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

QualityStocksNewsBreaks – QSAM Biosciences Inc. (QSAM) Expands IP Estate with Receipt of Third US Patent for CycloSam(R)

QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

Market Basics

Newsletter Publishers

Public Companies